Arcturus Therapeutics Holdings (ARCT) Stock Analysis & AI Equity Report
Arcturus Therapeutics Holdings (ARCT) overview
Arcturus Therapeutics Holdings (ARCT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 82.0m and operating profit of USD -76.3m; the year-end share price was 6.13 USD and market capitalisation was USD 174m. Arcturus Therapeutics Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arcturus Therapeutics Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Arcturus Therapeutics Holdings
Arcturus Therapeutics develops messenger RNA medicines, with a focus on therapeutics for liver and respiratory rare diseases and vaccines for infectious diseases. Its pipeline includes candidates for ornithine transcarbamylase deficiency and cystic fibrosis. The company uses its STARR self-amplifying mRNA and LUNAR lipid nanoparticle technologies to develop medicines and has partnered with CSL Seqirus on vaccine development and commercialization, including its approved KOSTAIVE COVID-19 vaccine.
Generate the Arcturus Therapeutics Holdings report
Arcturus Therapeutics Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Arcturus Therapeutics Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Arcturus Therapeutics Holdings
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.